ESMO: European Society for Medical Oncology

  1. Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative Early Breast Cancer

    Results from the BIG 1-98 study

  2. T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic Breast Cancer and Brain Metastases

    Results from the KAMILLA exploratory analysis

  3. FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer

    Approval is based on findings from the KEYNOTE‑177 study

  4. FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment

    Efficacy was investigated in the JAVELIN Bladder 100 trial 

  5. EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib

    It was intended for the treatment of tenosynovial giant cell tumour